For all intents and purposes in the context we care about here, this drug is still preclinical - we could literally have a human on Mars before this is available
so even though it's exciting...it might be smarter to manage your expectations about any single treatment vs being excited about the dozens of other preclinical treatments that could pay off
Here's some wild speculation (since that's the theme of the thread):
It could be the case that their relatively faster progress on phase I/II trials in women only signals that they're looking at it their product development much more sequentially than is being hoped here
ie get it near the end of phase III for endometriosis first, and only then move forward seriously on phase II for Androgenetic Alopecia
If there's obvious progress on the Androgenetic Alopecia side in a couple years, then I'm wrong about that (e.g. they're past the phase II subject recruitment stage)
this pattern would also be very similar to how finasteride itself was developed - despite knowing 100% it would also work for Androgenetic Alopecia, they waited until it was approved and in use for the prostate (and their investment recouped) before moving forward to get it approved for that 2nd indication (5 full years extra)